Instrument Inactif

Communiqués Intervacc AB (publ) Nasdaq Stockholm

Actions

SE0009607252

Recherche biotechnologique et médicale

Communiqués

24/08	Intervacc (Q2 Review): Key catalysts nearing	AQ
21/08	Intervacc: In the right direction – Q2 review	AQ
20/08	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ
30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
29/07	Intervacc: New Zealand order validates Strangvac’s position	AQ
29/07	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
04/06	Redeye initiates coverage of Intervacc	AQ
22/05	Intervacc: Positive results	AQ
22/05	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials	AQ
15/05	Intervacc: US progress, while European sales still soft – Q1 review	AQ
15/05	Emil Billbäck appointed new Chair of the Board of Intervacc	AQ
13/05	Report from Annual General Meeting in Intervacc	AQ
12/05	Intervacc strengthens management team for future growth	AQ
04/05	International Awareness Initiative Against Strangles	AQ
23/04	Intervacc brings together leading US and European experts to jointly tackle strangles	AQ
16/04	Unprecedented decision opens the way for the launch of Strangvac in Iceland	AQ
14/04	Intervacc publishes the 2025 Annual Report	AQ
10/04	Notice of Annual General Meeting in Intervacc AB (publ)	AQ
20/03	Intervacc: Highly promising data presented	AQ
19/03	Intervacc announces breakthrough protection against Streptococcus suis infection in piglets	AQ
09/03	Intervacc presents to the capital market on three occasions in March	AQ
18/02	Intervacc: Growth story remains despite weak quarter – Q4 review	AQ
17/02	Year-end report January - December 2025	AQ
06/02	Intervacc: New CEO announced	AQ
05/02	Intervacc announces change of CEO	AQ